Quantum computing's clearest potential advantage in drug discovery is not in screening millions of compounds or predicting drug properties—classical AI already handles those tasks well—but in the electronic-structure calculations at the heart of molecular modeling, where classical methods hit hard size and accuracy limits. A comparative analysis published in Frontiers in Drug Discovery maps each drug discovery task to its standard classical method and its quantum counterpart, and the pattern is consistent: near-term algorithms like the Variational Quantum Eigensolver (VQE) can run today but only on small systems, while the algorithms that would deliver high accuracy on large drug molecules, such as Quantum Phase Estimation (QPE), require fault-tolerant quantum computers expected after 2030.

The Computational Bottlenecks in Drug Discovery

The case for quantum computing rests on two problems that classical computation has not solved. The first is scale: a review in npj Drug Discovery by Yidong Zhou and colleagues estimates the chemical space of potential drug compounds at roughly 10^60 molecules, a space that vastly exceeds what classical algorithms can efficiently explore. The second is accuracy: the same review notes that conventional simulation methods struggle to accurately model the quantum-mechanical interactions that govern molecular behavior.

These limitations bite hardest where it matters most. The molecular interactions underlying drug action are, as the npj Drug Discovery authors put it, fundamentally quantum mechanical in nature, involving complex electron correlations and conformational dynamics that challenge classical computational methods. The result is a set of computational bottlenecks throughout the pharmaceutical pipeline that, in their assessment, affect both time-to-market and development success rates.

The practical consequences are visible in the standard toolkit. Density functional theory (DFT), the workhorse method for calculating molecular energies, becomes slow beyond roughly 100 atoms. CCSD(T), the most accurate classical method, only works up to about 30 atoms and is extremely slow beyond that. And docking software used for screening produces rough estimates that miss many good candidates, according to the Frontiers comparison.